Lucence Announces Medicare Reimbursement Decision for LiquidHALLMARK® Assay in Lung Cancer

PALO ALTO, Calif.–(BUSINESS WIRE)–Lucence announced today that Palmetto GBA, a Medicare administrative contractor and leader in evaluating molecular diagnostic technology through its laboratory technology assessment group for the Molecular Diagnostics Services program (MolDX), has finalized a foundational Local Coverage Determination (LCD) for the LiquidHALLMARK assay. The LCD covers all nine…